## **Supporting Information**

# Palladium-Catalyzed Monoselective C-H Borylation of Acetanilides under Acidic Conditions

Bin Xiao, Yi-Ming Li, Zhao-Jing Liu, Han-Yi Yang, and Yao Fu\*

Joint Laboratory of Green Synthetic Chemistry, Department of Chemistry, University of Science and Technology of China, Hefei 230026, China

fuyao@ustc.edu.cn

### List of Contents

1. Experimental Procedures for the Synthesis of 2a-2y	S2	
2. Optimization of the reaction conditions	S2	
3. NMR and HRMS Spectra of 2a-2y	S3 – S52	
4. Experimental Procedures for the Synthesis of 3a-3b	S53–S68	

#### **General Remark:**

PhCF<sub>3</sub> (>99%) and BQ was purchased from Aldrich and used without further treatment. (Bpin)<sub>2</sub> was recrystallized from EtOAc/Petroleum Ether (1:50) before being used. The 12% TsOH solution in HOAc was purchased from Acros. Analytical TLC was done on pre-coated *acidic alumina* plates (*i*Pr<sub>2</sub>O/EtOH 8:1). Column chromatography was conducted with 300-400 mesh *acidic alumina*. <sup>1</sup>H NMR spectra were recorded on 400 MHz spectrometers. <sup>13</sup>C NMR spectra were recorded on 100 MHz spectrometers. High-resolution mass spectra (HRMS) were recorded on a Thermo LTQ ORBITRAP XL spectrometer with ESI mode unless otherwise stated.

**Table S1**Optimization of the reaction conditions.<sup>a</sup>.

	NHAC	5 % Pd(OAc) <sub>2</sub> 2 equiv (Bpin) <sub>2</sub>	NHAc Bpin		
	1a		2a		
Entry	Additive	Oxidant	Solvent	Т	Yield % <sup>b</sup>
1	TsOH•H <sub>2</sub> O	benzoquinone	toluene	80 °C	7
2	TsOH•H <sub>2</sub> O+HOAc	benzoquinone	toluene	80 °C	14
3	TsOH•H <sub>2</sub> O+HOAc	benzoquinone	toluene	40 °C	55
4	TsOH•H <sub>2</sub> O+HOAc	o-chloranil	toluene	80 °C	23
5	TsOH•H <sub>2</sub> O+HOAc	o-chloranil	toluene	40 °C	0
6	12% TsOH in HOAc	benzoquinone	toluene	40 °C	66
7	12% TsOH in HOAc	benzoquinone	DCE	40 °C	67
8	12% TsOH in HOAc	benzoquinone	dioxane	40 °C	trace
9	12% TsOH in HOAc	benzoquinone	DMF	40 °C	0
10	12% TsOH in HOAc	benzoquinone	mesitylene	40 °C	77
11	12% TsOH in HOAc	benzoquinone	PhCF <sub>3</sub>	40 °C	80
12	12% TsOH in HOAc	$Cu(OAc)_2$	PhCF <sub>3</sub>	40 °C	0
13	12% TsOH in HOAc	AgOAc	PhCF <sub>3</sub>	40 °C	0
14	TFA	benzoquinone	PhCF <sub>3</sub>	40 °C	trace
15	TFA	AgOAc	PhCF <sub>3</sub>	40 °C	trace
16	12% TsOH in HOAc	benzoquinone	PhCF <sub>3</sub>	30 °C	87(70 <sup>c</sup> )
17	12% TsOH in HOAc	benzoquinone	PhCF <sub>3</sub>	25 °C	76

<sup>*a*</sup> All the reactions were carried out in 0.3 mmol scale with 0.1 mmol of additive (TsOH or TFA) and 2 equiv of oxidant in 0.4 mL solvent and 0.1 mL HOAc (if used). <sup>*b*</sup> GC yields with benzophenone as an internal standard. <sup>*c*</sup> Isolated yield.

#### General Procedure for The Synthesis of 2a-2x:

To a 10 mL vial was sequentially added  $Pd(OAc)_2$  (3.4 mg, 0.015 mmol), acetanilide (0.3 mmol),  $B_2pin_2$  (152 mg, 0.6 mmol), BQ (65 mg, 0.6 mmol) and PhCF<sub>3</sub> (0.4 mL). After the reaction was stirred at room temperature for 2 min, TsOH (12% in HOAc, 133uL, 0.1 mmol) was added. The vial was stirred at the 30 °C for 36-48 h. The reaction mixture was diluted with 0.5 mL CHCl<sub>3</sub>-EtOH (20:1) and then loaded onto the top of a short (diameter of 2 cm, 10 cm long ) *acidic alumina* column slurry-packed with CHCl<sub>3</sub>-EtOH (20:1). The crude product containing un-reacted starting material was soon obtained by eluting with CHCl<sub>3</sub>-EtOH (20:1). The solution of crude product was evaporated, and then 10 mL EtOAc/Petroleum ether (1:5, for most of substrates, and 1:10 for **2e**, **2r**, **2u-2x**) was added. After sedimentation for 1 hour at room temperature, the desired product was filtered out as white or light pink solid.

The procedure for gram-scale synthesis of 2y is similar to 2a-x. A 25 mL round-bottomed flask was used instead of a 10 mL vial. Column chromatography was conducted with *acidic alumina* column (diameter of 5 cm, 15 cm long).

NHAc Me Bpin

*N*-(4-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide <sup>1</sup>H NMR (400 MHz, DMSO)  $\delta$  7.20 (s, 1H), 7.04 (d, *J* = 8.0, 1H), 6.91 (d, *J* = 8.0, 1H), 2.26 (s, 3H), 2.24 (s, 3H), 1.17 (s, 12H). <sup>13</sup>C NMR (100 MHz, DMSO)  $\delta$  169.04, 135.71, 133.78, 132.92, 128.00, 115.40, 79.49, 25.95, 21.61, 20.82. HRMS requires [C15H22BNO3+H]<sup>+</sup> 276.1766, found ESI [M+H]<sup>+</sup> 276.1764.





F<sub>3</sub>CO NHAc

*N*-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(trifluoromethoxy)phenyl)acetamide <sup>1</sup>H NMR (400 MHz, DMSO)  $\delta$  7.51 (d, *J* = 8.2, 1H), 7.13 (d, *J* = 7.7, 1H), 7.00 (s, 1H), 2.29 (s, 3H), 1.18 (s, 12H).

<sup>13</sup>C NMR (100 MHz, DMSO) δ 170.74, 147.64, 139.10, 134.66, 120.01, 117.46, 107.80, 79.86, 25.87, 21.88.

HRMS requires [C15H19BF3NO4+H]<sup>+</sup> 346.1432, found ESI [M+H]<sup>+</sup> 346.1434.







*N*-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(trifluoromethyl)phenyl)acetamide <sup>1</sup>H NMR (400 MHz, DMSO)  $\delta$  7.66 (s, 1H), 7.61 (dd, *J* = 8.4, 1.7, 1H), 7.19 (d, *J* = 8.4, 1H), 2.34 (s, 3H), 1.19 (s, 12H). <sup>13</sup>C NMR (100 MHz, DMSO)  $\delta$  171.37, 140.86, 129.14 (q, *J* = 4 Hz), 125.55 (q, *J* =

31 Hz) (126.01, 125.70, 125.39, 125.08.), 124.49 (q, *J* = 4 Hz), 124.48 (q, *J* = 270 Hz)

(128.53, 125.83, 123.13, 120.43), 116.12, 79.75, 25.92, 21.82.

HRMS requires [C15H19BF3NO3+H]<sup>+</sup> 330.1483, found ESI [M+H]<sup>+</sup> 330.1483.







ethyl 2-(4-acetamido-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate

<sup>1</sup>H NMR (400 MHz, DMSO)  $\delta$  7.30 (s, 1H), 7.13 (d, J = 8.1, 1H), 6.97 (d, J = 8.1,

1H), 4.06 (q, *J* = 7.0, 2H), 3.59 (s, 2H), 2.25 (s, 3H), 1.18 (m, 15H).

13C NMR (100 MHz, DMSO) δ 171.19, 169.52, 136.78, 133.21, 130.96, 128.36, 115.53, 79.54, 60.08, 40.29, 25.93, 21.63, 13.96.

HRMS requires [C18H26BNO5+H]<sup>+</sup> 348.1977, found ESI [M+H]<sup>+</sup> 348.1977.







N-(3-chloro-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide

<sup>1</sup>H NMR (400 MHz, DMSO) δ 7.26 (m, 2H), 2.35 (s,3H), 2.31 (s, 3H), 1.17 (s, 12H).

<sup>13</sup>C NMR (100 MHz, DMSO) δ 171.30, 140.28, 138.15, 133.08, 131.21, 125.86,

123.61, 80.19, 25.66, 22.10, 14.14.

HRMS requires [C15H21BCINO3+H]<sup>+</sup> 310.1376, found ESI [M+H]<sup>+</sup> 310.1374.







N-(4-bromo-5-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide

<sup>1</sup>H NMR (400 MHz, DMSO) δ 7.47 (s, 1H), 6.95 (s, 1H), 2.31 (s, 3H), 2.27 (s, 3H),

1.16 (s, 12H).

<sup>13</sup>C NMR (100 MHz, DMSO) δ 170.19, 137.33, 137.22, 136.03, 135.66, 120.59,

118.00, 79.54, 25.91, 22.29, 21.68.

HRMS requires [C15H21BBrNO3+H]<sup>+</sup> 354.0871, found ESI [M+H]<sup>+</sup> 354.0870.







<sup>13</sup>C NMR (100 MHz, DMSO) δ 170.06, 153.86, 137.93, 133.41, 117.59, 100.64, 79.79, 55.77, 25.81, 21.88.

HRMS requires  $[C15H21BCINO4+H]^+$  326.1325, found ESI  $[M+H]^+$  326.1324.







*N*-(4-(4-chlorophenoxy)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide <sup>1</sup>H NMR (400 MHz, DMSO)  $\delta$  7.41 (d, *J* = 7.7, 2H), 7.19 – 6.74 (m, 5H), 2.28 (s, 3H),

1.11 (s, 12H).

<sup>13</sup>C NMR (100 MHz, DMSO) δ 169.39, 156.13, 153.22, 133.93, 129.71, 129.65,

126.57, 122.06, 119.53, 118.31, 117.28, 79.37, 25.86, 21.46.

HRMS requires [C20H23BCINO4+H]<sup>+</sup> 388.1481, found ESI [M+H]<sup>+</sup> 388.1480.





Br NHAc Me Bpin

N-(5-bromo-4-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide

<sup>1</sup>H NMR (400 MHz, DMSO) δ 7.31 (s, 1H), 7.25 (s, 1H), 2.30 (s, 3H), 2.25 (s, 3H),

1.17 (s, 12H).

<sup>13</sup>C NMR (100 MHz, DMSO) δ 169.95, 137.36, 134.96, 133.44, 122.54, 118.79,

79.83, 25.86, 21.89, 21.85.

HRMS requires [C15H21BBrNO3+H]<sup>+</sup> 354.0871, found ESI [M+H]<sup>+</sup> 354.0869.







N-(5-chloro-4-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide

<sup>1</sup>H NMR (400 MHz, DMSO) δ 7.31 (s, 1H), 7.09 (s, 1H), 2.28 (s, 3H), 2.25 (s, 3H),

1.17 (s, 12H).

<sup>13</sup>C NMR (100 MHz, DMSO) δ 169.96, 137.32, 135.22, 132.00, 131.65, 115.67,

79.85, 25.86, 21.87, 19.11.

HRMS requires [C15H21BCINO3+H]<sup>+</sup> 310.1376, found ESI [M+H]<sup>+</sup> 310.1373.







N-(2-bromo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide

<sup>1</sup>H NMR (400 MHz, DMSO)  $\delta$  7.52 – 7.32 (m, 2H), 6.96 (d, J = 8.4, 1H), 2.29 (s, 3H),

1.16 (s, 12H).

<sup>13</sup>C NMR (100 MHz, DMSO) δ 170.26, 136.78, 134.66, 130.04, 117.93, 117.84,

79.53, 25.96, 21.63.

HRMS requires [C14H19BBrNO3+H]<sup>+</sup> 340.0714, found ESI [M+H]<sup>+</sup> 340.0715.







N-(2-chloro-4-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide

<sup>1</sup>H NMR (400 MHz, DMSO) δ 7.23 (s, 1H), 7.18 (s, 1H), 2.33 (s, 3H), 2.27 (s, 3H),

1.18 (s, 12H).

<sup>13</sup>C NMR (100 MHz, DMSO) δ 171.37, 136.06, 132.25, 131.79, 128.73, 120.70,

80.18, 25.72, 21.98, 20.25.

HRMS requires  $[C15H21BCINO3+H]^+$  310.1376, found ESI  $[M+H]^+$  310.1376.







N-(3-fluoro-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide

<sup>1</sup>H NMR (400 MHz, DMSO)  $\delta$  7.28 (t, J = 7.5, 1H), 6.97 (t, J = 8.9, 1H), 2.29 (s, 3H),

2.19 (s, 3H), 1.18 (s, 12H).

<sup>13</sup>C NMR (100 MHz, DMSO) δ 171.05, 160.34 (d, J = 239 Hz), 138.43, 131.28 (d, J =

9.2 Hz), 113.23 (d, *J* = 18 Hz), 111.88 (d, *J* = 22 Hz), 80.28, 25.62, 22.10, 8.83.

HRMS requires [C15H21BFNO3+H]<sup>+</sup> 294.1671, found ESI [M+H]<sup>+</sup> 294.1669.







4-acetamido-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl 4-methylbenzenesulfonate

<sup>1</sup>H NMR (400 MHz, DMSO)  $\delta$  7.71 (d, J = 8.0, 2H), 7.46 (d, J = 7.7, 2H), 6.99 (s,

2H), 6.78 (s, 1H), 2.41 (s, 3H), 2.26 (s, 3H), 1.04 (s, 12H).

<sup>13</sup>C NMR (100 MHz, DMSO) δ 170.22, 146.41, 145.44, 136.29, 131.65, 130.10,

128.02, 124.80, 121.48, 117.06, 79.34, 25.78, 21.51, 21.05.

HRMS requires [C21H26BNO6S+H]<sup>+</sup> 432.1647, found ESI [M+H]<sup>+</sup> 432.1646.







4-acetamido-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl acetate

<sup>1</sup>H NMR (400 MHz, DMSO) δ 7.01 (m, 3H), 2.28 (s, 3H), 2.25 (s, 3H), 1.15 (s, 12H).

<sup>13</sup>C NMR (100 MHz, DMSO) δ 169.66, 169.30, 147.79, 135.23, 124.70, 120.91,

116.55, 79.44, 25.95, 21.51, 20.76.

HRMS requires [C16H22BNO5+H]<sup>+</sup> 320.1664, found ESI [M+H]<sup>+</sup> 320.1664.







4-acetamido-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl pivalate

<sup>1</sup>H NMR (400 MHz, DMSO) δ 6.99 (m, 3H), 2.28 (s, 3H), 1.29 (s, 9H), 1.15 (s, 12H).

<sup>13</sup>C NMR (100 MHz, DMSO) δ 176.48, 169.66, 148.03, 135.26, 124.46, 120.79,

116.63, 79.49, 38.40, 26.68, 25.93, 21.54.

HRMS requires [C19H28BNO5+H]<sup>+</sup> 362.2133, found ESI [M+H]<sup>+</sup> 362.2132.







diethyl 4-acetamido-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzylphosphonate <sup>1</sup>H NMR (400 MHz, DMSO)  $\delta$  7.33 (s, 1H), 7.13 (d, *J* = 8.0, 1H), 6.95 (d, *J* = 8.0, 1H), 4.29 – 3.65 (m, 4H), 3.15 (d, *J* = 21.3, 2H), 2.25 (s, 3H), 1.17 (m, 18H). <sup>13</sup>C NMR (100 MHz, DMSO)  $\delta$  169.43, 136.55, 133.88, 128.92, 128.60, 115.38, 79.52, 61.19, 32.04, 25.95, 21.64, 16.90.

HRMS requires  $[C19H31BNO6P+H]^+ 412.2055$ , found ESI  $[M+H]^+ 412.2054$ .







*N*-(2,2-difluoro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[*d*][1,3]dioxol-5-yl)acetamide <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.17 (s, 1H), 7.00 (s, 1H), 2.29 (s, 3H), 1.16 (s, 12H). <sup>13</sup>C NMR (100 MHz, DMSO) δ 170.02, 141.91, 140.49, 133.59, 131.03, 112.14, 98.47, 79.57, 25.98, 21.55.

HRMS requires [C15H18BF2NO5+H]<sup>+</sup> 342.1319, found ESI [M+H]<sup>+</sup> 342.1317.







1-(8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroquinolin-1(2*H*)-yl)ethanone <sup>1</sup>H NMR (400 MHz, DMSO)  $\delta$  7.28 (d, *J* = 6.7, 1H), 7.16 – 6.78 (m, 2H), 4.35 – 3.71 (t, *J* =5.5, 2H), 2.77 (t, *J* = 5.5, 2H), 2.46 (s, 3H), 1.96 (q, *J* = 5.5, 2H), 1.14 (s, 12H). <sup>13</sup>C NMR (100 MHz, DMSO)  $\delta$  170.96, 136.40, 129.84, 127.42, 125.51, 125.17, 78.98, 47.62, 26.67, 25.96, 22.58, 21.15.

HRMS requires [C17H24BNO3+H]<sup>+</sup> 302.1922, found ESI [M+H]<sup>+</sup> 302.1921.







4-acetamido-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenethyl acetate

<sup>1</sup>H NMR (400 MHz, DMSO) δ 7.26 (s, 1H), 7.12 (d, *J* = 8.1, 1H), 6.95 (d, *J* = 8.1, 1H), 4.16 (t, *J* = 6.7, 2H), 2.84 (t, *J* = 6.7, 2H), 2.25 (s, 3H), 1.97 (s, 3H), 1.17 (s, 12H).

<sup>13</sup>C NMR (100 MHz, DMSO) δ 170.20, 169.35, 136.49, 134.53, 132.89, 127.87, 115.53, 79.51, 64.41, 34.07, 25.93, 21.62, 20.60.

HRMS requires [C18H26BNO5+H]<sup>+</sup> 348.1977, found ESI [M+H]<sup>+</sup> 348.1974.







*N*-(4-(3-bromopropoxy)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide <sup>1</sup>H NMR (400 MHz, DMSO)  $\delta$  6.94 (d, *J* = 8.6, 1H), 6.92 (d, *J* = 2.8, 1H), 6.82 (dd, *J* = 8.6, 2.8, 1H), 4.04 (t, *J* = 6.0, 2H), 3.67 (t, *J* = 6.5, 2H), 2.33 – 2.13 (m, 5H), 1.16 (s, 12H).

<sup>13</sup>C NMR (100 MHz, DMSO) δ 168.44, 155.83, 131.50, 117.09, 116.68, 113.68, 79.29, 65.09, 31.77, 31.28, 25.97, 21.36.

HRMS requires [C17H25BBrNO4+H]<sup>+</sup> 398.1133, found ESI [M+H]<sup>+</sup> 398.1131.

Electronic Supplementary Material (ESI) for Chemical Communications This journal is The Royal Society of Chemistry 2012







*N*-(4-(6-chlorohexyloxy)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide <sup>1</sup>H NMR (400 MHz, DMSO)  $\delta$  6.92 (d, *J* = 8.6, 1H), 6.89 (d, *J* = 2.8, 1H), 6.79 (dd, *J* = 8.6, 2.8, 1H), 3.91 (t, *J* = 6.4, 2H), 3.63 (t, *J* = 6.6, 2H), 2.24 (s, 3H), 1.72 (m, 4H), 1.52 - 1.32 (m, 4H), 1.16 (s, 12H).

<sup>13</sup>C NMR (100 MHz, DMSO) δ 168.33, 156.12, 131.25, 117.04, 116.63, 113.60,

79.28, 67.12, 45.24, 31.88, 28.47, 25.95, 24.79, 24.74, 21.35.

HRMS requires [C20H31BClNO4+H]<sup>+</sup> 396.2107, found ESI [M+H]<sup>+</sup> 396.2108.







4-acetamido-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenethyl 4-methylbenzenesulfonate <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.68 (d, *J* = 8.0, 2H), 7.41 (d, *J* = 8.0, 2H), 7.19 (s, 1H), 7.00 (d, *J* = 8.1, 1H), 6.89 (d, *J* = 8.1, 1H), 4.16 (t, *J* = 6.4, 2H), 2.83 (t, *J* = 6.4, 2H), 2.40 (s, 3H), 2.26 (s, 3H), 1.17 (s, 12H). <sup>13</sup>C NMR (100 MHz, DMSO) δ 169.42, 144.65, 136.71, 133.16, 133.00, 132.16, 129.99, 127.82, 127.41, 115.55, 79.56, 71.06, 34.14, 25.91, 21.65, 20.99.

HRMS requires [C23H30BNO6S+H]<sup>+</sup> 460.1960, found ESI [M+H]<sup>+</sup> 460.1959.







N-(4-methoxy-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide

<sup>1</sup>H NMR (400 MHz, DMSO)  $\delta$  6.94 (d, J = 8.6, 1H), 6.91 (s, 1H), 6.80 (d, J = 8.6,

1H), 3.71 (s, 3H), 2.24 (s, 3H), 1.16 (s, 12H).

<sup>13</sup>C NMR (101 MHz, DMSO) δ 168.38, 156.72, 131.35, 116.65, 116.44, 113.01,

79.30, 54.83, 25.95, 21.35.

HRMS requires [C19H28BNO5+H]<sup>+</sup> 292.1715, found ESI [M+H]<sup>+</sup> 292.1715.







#### Synthesis of 3a and 3b via Suzuki Coupling:

N-(4-methoxy-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide (**2y**) (73 mg, 0.25 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (4.6 mg, 0.005 mmol), S-Phos (8.2 mg, 0.02 mmol) and K<sub>2</sub>CO<sub>3</sub> (104 mg, 0.75 mmol) were placed in a vial under Ar. Aryl-Br (0.2 mmol) and then a mixed solvent of 0.4 mL toluene, 0.4 mL EtOH and 0.2 mL H<sub>2</sub>O was added. The mixture was violently stirred at 100 °C overnight and cooled to room temperature. The organic phase was purified by flash chromatography to give desired product as white solid.



MeÓ

### (s)-N-(5-methoxy-2',6'-dimethylbiphenyl-2-yl)acetamide

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.24 (d, J = 9.0, 1H), 7.23 (t, J = 7.3, 1H), 7.16 (d, J = 7.3, 2H), 6.92 (d, J = 9.0, 1H), 6.61 (s, 1H), 6.53 (s, 1H), 3.79 (s, 3H), 2.01 (s, 6H),

1.90 (s, 3H).

 $^{13}\text{C}$  NMR (100 MHz, CDCl\_3)  $\delta$  167.87, 156.18, 136.92, 136.25, 131.72, 128.61,

128.29, 127.93, 122.42, 114.62, 113.08, 55.46, 24.47, 20.20.

HRMS (EI) calcd for C17H19NO2: 269.1416; found: 269.1392.







MeÓ

N-(4-methoxy-2-(thiazol-2-yl)phenyl)acetamide

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  11.85 (s, 1H), 8.65 (d, J = 9.1, 1H), 7.87 (d, J = 2.0,

1H), 7.35 (d, *J* = 2.0, 1H), 7.26 (s, 1H), 6.98 (d, *J* = 9.1, 1H), 3.84 (s, 3H), 2.23 (s, 3H).

 $^{13}C$  NMR (100 MHz, CDCl\_3)  $\delta$  168.71, 155.00, 142.49, 130.81, 122.54, 120.36,

118.47, 116.14, 113.92, 55.67, 25.31.

HRMS (EI) calcd for C12H12N2O2S: 248.0619; found: 248.0626.



S55

#### Synthesis of 4a-g:

**2** (0.2 mmol), CuTc (7.6 mg, 0.04 mmol), 5-(trifluoromethyl)dibenzothiophenium tetrafluoroborate (81.6 mg, 0.24 mmol), 2,4,6-Collidine (24.2 mg, 0.2 mmol) and KOH (16.8 mg, 0.3 mmol) were placed in a vial. 1.0 mL DMAc was added. The mixture was stirred at 80 °C for 8 h and cooled to room temperature. EtOAc and H<sub>2</sub>O was added and then the organic phase was purified by flash chromatography to give desired product as white solid.



Chemical Formula: C<sub>10</sub>H<sub>9</sub>BrF<sub>3</sub>NO Exact Mass: 294.9820

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.39 (s, 1H), 7.43 (s, 1H), 7.34 (s, 1H), 7.27 (s, 1H), 2.40 (s, 3H), 2.21 (s, 3H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.44, 134.78, 133.68, 129.49, 128.53, 127.58 (q, *J* = 5.4 Hz), 123.90 (q, *J* = 271 Hz) (127.97, 125.26, 122.55, 119.84), 119.36 (q, *J* = 28.4 Hz) (119.81, 119.50, 119.22, 118.93), 24.67, 22.57.







Chemical Formula: C<sub>14</sub>H<sub>16</sub>F<sub>3</sub>NO<sub>3</sub> Exact Mass: 303.1082

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.15 (d, *J* = 8.7, 1H), 7.40 (s, 1H), 7.32 (s, 1H), 7.25 (d, *J* = 8.7, 1H), 2.21 (s, 3H), 1.36 (s, 9H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 176.89, 168.56, 147.36, 132.68, 126.26, 126.04, 123.47 (q, *J* = 271 Hz) (127.55, 124.83, 122.12, 119.40), 121.55 (q, *J* = 30.0 Hz) (122.00, 121.70, 121.40, 121.11), 119.55 (119.69, 119.64, 119.58, 119.53), 39.26, 27.17, 24.63.









Chemical Formula: C<sub>15</sub>H<sub>11</sub>CIF<sub>3</sub>NO<sub>2</sub> Exact Mass: 329.0430

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.02 (m, 1H), 7.32 (m, 3H), 7.24 (m, 1H), 7.14 (m, 1H), 6.95 (m, 2H), 2.22 (s, 3H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.66, 155.14, 153.83, 130.49, 130.19, 129.35, 127.54, 122.64, 120.45, 116.46 (q, *J* = 5.4 Hz) (116.54, 116.49, 116.43, 116.38), 24.52.







Chemical Formula: C<sub>10</sub>H<sub>10</sub>F<sub>3</sub>NO<sub>2</sub> Exact Mass: 233.0664

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.86 (d, J = 8.9, 1H), 7.22 (s, 1H), 7.12 (d, J = 2.7, 1H), 7.06 (dd, J = 8.9, 2.8, 1H), 3.83 (s, 4H), 2.19 (s, 3H).

 $^{19}\text{F}$  NMR (376 MHz, CDCl<sub>3</sub>)  $\delta$  -61.07.

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.76, 156.78, 127.95, 127.82, 123.77 (q, *J* = 271 Hz) (127.64, 125.13, 122.41, 119.78), 123.14 (q, *J* = 30 Hz) (123.59, 123.29, 123.00, 122.69), 117.82, 111.84, 111.78, 55.84, 24.31.









<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.13 (d, J = 8.1, 1H), 7.53 (s, 1H), 7.47 (d, J = 8.4, 1H), 7.39 (s, 1H), 4.16 (q, J = 7.1, 2H), 3.62 (s, 2H), 2.21 (s, 3H), 1.26 (t, J = 7.1, 3H).

<sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ -60.65.

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 170.92, 168.53, 134.29, 133.88, 130.79, 126.99 (q, *J* = 5.4 Hz) (127.07, 127.02, 126.96, 126.91), 125.00, 120.47 (q, *J* = 30 Hz), 61.33, 40.65, 24.76, 14.27.





<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.86 (d, J = 8.9, 1H), 7.19 (s, 1H), 7.11 (s, 1H), 7.05 (d, J = 8.9, 1H), 3.97 (t, J = 6.3, 2H), 3.56 (t, J = 6.6, 2H), 2.19 (s, 3H), 1.82 (m, 4H), 1.54 – 1.47 (m, 4H).

 $^{19}\text{F}$  NMR (376 MHz, CDCl<sub>3</sub>)  $\delta$  -61.03.

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.75, 156.25, 127.87, 127.65, 123.79 (q, *J* = 271 Hz), 123.07 (q, *J* = 30 Hz) 119.69, 118.25, 112.41 (q, *J* = 5.4 Hz) (112.49, 112.44, 112.38, 112.33), 68.44, 45.10, 32.61, 29.09, 26.73, 25.48, 24.37.



